Introduction::The development of novel antibiotics is urgently needed due to the rise in
multidrug-resistant (MDR) infections globally. Marine microorganisms have emerged as unexplored
sources of bioactive compounds with unique mechanisms to combat antimicrobial resistance (AMR).
Methods::This review summarizes peer-reviewed and recent research from PubMed, Scopus, and
Web of Science to evaluate the scope of marine-derived metabolites against AMR pathogens. The
focus was on studies describing antimicrobial metabolites produced by marine actinomycetes, bacteria,
and fungi. Studies involving non-resistant pathogens or non-marine sources were excluded.
Results::The review identifies various secondary metabolites, including peptides, polyketides, macrolides,
fatty acid amines, equisetin, and aminolipids. These compounds target AMR pathogens such
as MRSA, VRE, and VRSE. Marine actinomycetes—including Streptomyces spp., Micromonospora
spp., and Verrucosispora spp.—are key producers of antimicrobial compounds. Likewise, marine
bacterial species such as Bacillus spp., Aequorivita spp., and Zobellia galactanivorans, as well as
fungal species like Penicillium spp. and Fusarium spp., produce bioactive compounds.
Discussion::These findings highlight the potential of marine microbes as sources of novel antibiotics.
Despite this potential, several limitations persist, including scalability issues, the noncultivability
of many microbes, toxicology concerns, source-dependent variability, and insufficient in
vivo validation. These challenges can be addressed by integrating modern omics technologies to
advance drug discovery for AMR.
Conclusion::This review underscores marine microbes as promising sources in the fight against
AMR. To unlock their full potential, greater interdisciplinary collaboration is needed to develop sustainable
solutions, accelerate antibiotic discovery, and address the global AMR crisis.